Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Top Performance

Predictions

sell
Incyte Corp.

Start price
Target price
Perf. (%)
€72.06
20.12.20
-
20.12.21
-7.02%
21.02.21

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Dependend from some customers or products
SpringheelJack 
20.12.20 50%
buy
Bayer AG

Start price
Target price
Perf. (%)
€48.85
19.12.20
€62.00
22.06.21
7.59%
22.06.21

Undervalued
Well known brand
Future proof or reliable business model
Top 10 in its market
Snowman 
19.12.20 50%
sell
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€48.01
18.12.20
€45.00
-1.78%
23.12.20

Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Traumtanz 
18.12.20 50%
sell
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€48.17
18.12.20
€27.00
18.06.21
14.83%
19.01.21

Top 10 in its market
Good rating
Medium risks for its business
Bad culture
Snowman 
18.12.20 50%
buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€31.01
18.12.20
€34.00
18.12.21
-5.35%
15.03.21

Small challenges to pay loans and raise capital
Innovative
Very small cyclical dependencies
Some uniques
Snowman 
18.12.20 80%
buy
Medigene AG

Start price
Target price
Perf. (%)
€3.56
18.12.20
-
18.12.21
8.86%
27.02.21

Innovative
Dependend from some customers or products
Higher risks for its business
ElectricPlayer 
18.12.20 50%
buy
AstraZeneca plc

Start price
Target price
Perf. (%)
€83.36
18.12.20
€90.00
-3.42%
11.03.21

Could be worthwhile Investment >10% per year
Higher risks for its business
phonebroker 
18.12.20 50%
buy
Bayer AG

Start price
Target price
Perf. (%)
€49.67
18.12.20
€57.00
18.12.21
3.14%
09.07.21

Undervalued
Risky Investment
phonebroker 
18.12.20 50%
buy
Astrazeneca ADR

Start price
Target price
Perf. (%)
€41.60
17.12.20
€48.00
17.12.21
9.86%
03.06.21

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Rising EBIT margin expected
ValueFreak 
17.12.20 50%
sell
Pfizer Inc.

Start price
Target price
Perf. (%)
€30.91
17.12.20
€29.00
-1.81%
21.12.20

Capable Management
Good culture
Innovative
Differentiated customer and product portfolio
Traumtanz 
17.12.20 50%
buy
Jaguar Health Inc.

Start price
Target price
Perf. (%)
€61.20
14.12.20
€225.00
1282.35%
11.01.21

Could be worthwhile Investment >10% per year
DomRuinart 
14.12.20 50%
buy
Avinger Inc.

Start price
Target price
Perf. (%)
€4.88
14.12.20
€20.00
301.64%
11.01.21

Could be worthwhile Investment >10% per year
DomRuinart 
14.12.20 50%
buy
Atossa Genetics Inc

Start price
Target price
Perf. (%)
€0.72
14.12.20
€2.00
14.12.21
9.69%
11.01.21

Could be worthwhile Investment >10% per year
DomRuinart 
14.12.20 50%
buy
InVivo Therapeutics Holdings

Start price
Target price
Perf. (%)
€13.00
14.12.20
€25.00
14.12.21
71.15%
11.01.21

Could be worthwhile Investment >10% per year
DomRuinart 
14.12.20 50%
buy
Nuwellis Inc.

Start price
Target price
Perf. (%)
€6.00
14.12.20
€8.00
14.12.21
6.67%
11.01.21

Could be very worthwhile Investment >20% year
DomRuinart 
14.12.20 50%
buy
iBio Inc.

Start price
Target price
Perf. (%)
€25.75
14.12.20
€50.00
14.12.21
-45.17%
15.12.21

Could be worthwhile Investment >10% per year
Future proof or reliable business model
yester 
14.12.20 50%
sell
Evolus Inc

Start price
Target price
Perf. (%)
€3.13
14.12.20
-
-10.64%
28.12.20

Risky Investment
blaugold 
14.12.20 50%
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€4.36
13.12.20
-
13.12.21
-5.96%
10.01.21

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
Taurito 
13.12.20 50%
buy
Catalyst Pharmaceutical Partners Inc

Start price
Target price
Perf. (%)
€3.06
13.12.20
-
13.12.21
1.50%
11.03.21

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Savour 
13.12.20 50%
buy
Nanostr.technol.

Start price
Target price
Perf. (%)
€57.50
13.12.20
-
13.12.21
-41.91%
14.12.21

Risky Investment
Maxfloh 
13.12.20 50%
buy
Ionis Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€37.79
13.12.20
-
13.12.21
-29.55%
14.12.21

Risky Investment
Maxfloh 
13.12.20 50%
buy
Alexion Pharmaceutical Inc.

Start price
Target price
Perf. (%)
€142.00
13.12.20
€170.00
13.12.21
9.00%
14.12.21

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
skatcup 
13.12.20 100%
sell
Curis Inc.

Start price
Target price
Perf. (%)
€6.35
13.12.20
-
13.12.21
37.01%
16.02.21

Below average Marketposition
Probably not worthwhile Investment
Significant cyclical dependencies
Little known brand
tinelchen 
13.12.20 50%
sell
Lexicon Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€2.66
13.12.20
-
13.12.21
143.95%
16.02.21

Probably not worthwhile Investment
Significant cyclical dependencies
tinelchen 
13.12.20 50%
sell
PhaseBio Pharmaceuticals Inc

Start price
Target price
Perf. (%)
€3.60
12.12.20
-
12.12.21
-42.22%
13.12.21

Probably not worthwhile Investment
PlusUltra 
12.12.20 50%